Insulet Co. (PODD) Shares Sold by Kopp Investment Advisors LLC

Kopp Investment Advisors LLC reduced its stake in Insulet Co. (NASDAQ:PODD) by 4.9% in the 4th quarter, Holdings Channel reports. The firm owned 42,614 shares of the medical instruments supplier’s stock after selling 2,219 shares during the period. Insulet comprises about 2.9% of Kopp Investment Advisors LLC’s holdings, making the stock its 12th biggest position. Kopp Investment Advisors LLC’s holdings in Insulet were worth $2,940,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in the stock. HBK Investments L P purchased a new position in shares of Insulet in the 4th quarter valued at approximately $1,615,000. Two Sigma Investments LP raised its position in shares of Insulet by 1,484.2% in the 4th quarter. Two Sigma Investments LP now owns 278,994 shares of the medical instruments supplier’s stock valued at $19,251,000 after purchasing an additional 261,383 shares during the last quarter. Two Sigma Advisers LP raised its position in shares of Insulet by 114.8% in the 4th quarter. Two Sigma Advisers LP now owns 418,805 shares of the medical instruments supplier’s stock valued at $28,898,000 after purchasing an additional 223,800 shares during the last quarter. Fred Alger Management Inc. raised its position in shares of Insulet by 32.5% in the 4th quarter. Fred Alger Management Inc. now owns 1,808,616 shares of the medical instruments supplier’s stock valued at $124,795,000 after purchasing an additional 443,970 shares during the last quarter. Finally, AMP Capital Investors Ltd acquired a new position in Insulet in the 4th quarter worth approximately $269,000.

How to Become a New Pot Stock Millionaire

In related news, COO Shacey Petrovic sold 1,319 shares of Insulet stock in a transaction on Tuesday, March 6th. The shares were sold at an average price of $76.81, for a total value of $101,312.39. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director David A. Lemoine sold 641 shares of Insulet stock in a transaction on Tuesday, March 6th. The shares were sold at an average price of $76.81, for a total transaction of $49,235.21. The disclosure for this sale can be found here. 2.60% of the stock is currently owned by company insiders.

Several equities analysts recently weighed in on the stock. Zacks Investment Research downgraded shares of Insulet from a “hold” rating to a “sell” rating in a report on Friday, February 23rd. BidaskClub upgraded shares of Insulet from a “hold” rating to a “buy” rating in a report on Friday. Barclays reiterated an “overweight” rating and issued a $90.00 price target (up previously from $85.00) on shares of Insulet in a report on Thursday, February 22nd. Cowen reiterated an “outperform” rating and issued a $90.00 price target (up previously from $80.00) on shares of Insulet in a report on Thursday, February 22nd. Finally, Oppenheimer set a $82.00 price target on shares of Insulet and gave the stock a “hold” rating in a report on Thursday, February 22nd. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and thirteen have given a buy rating to the company’s stock. Insulet has an average rating of “Buy” and an average price target of $73.24.

Shares of Insulet Co. (NASDAQ PODD) opened at $80.33 on Monday. Insulet Co. has a one year low of $38.43 and a one year high of $83.56. The company has a current ratio of 6.24, a quick ratio of 5.85 and a debt-to-equity ratio of 3.57.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Wednesday, February 21st. The medical instruments supplier reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.04). Insulet had a negative return on equity of 29.73% and a negative net margin of 5.79%. The firm had revenue of $130.50 million for the quarter, compared to analyst estimates of $125.16 million. During the same period in the previous year, the business earned ($0.16) EPS. Insulet’s revenue for the quarter was up 26.0% compared to the same quarter last year. equities analysts forecast that Insulet Co. will post -0.3 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This piece was first published by Markets Daily and is the property of of Markets Daily. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://www.themarketsdaily.com/2018/03/12/insulet-co-podd-shares-sold-by-kopp-investment-advisors-llc.html.

Insulet Company Profile

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Co. (NASDAQ:PODD).

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply